Home › Squamous Cell Carcinoma › Tennessee
Squamous Cell Carcinoma clinical trials in Tennessee
7 studies for Squamous Cell Carcinoma are looking for participants at sites in Tennessee.
Cities in Tennessee
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06561685Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT06819228Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07460765Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 11, 2026 · NCT07217028High-Resolution PET-CT Imaging for Surgical Margin Visualization
- Vanderbilt University Medical Center, Nashville
Recruiting
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT06915454Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 15, 2025 · NCT04429542From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.